|
Oct 5
|
Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years
|
|
Oct 4
|
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
|
|
Oct 3
|
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
|
|
Oct 3
|
Gilead signs agreements to facilitate access to HIV prevention drug
|
|
Oct 2
|
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
|
|
Oct 2
|
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
|
|
Sep 25
|
Championing HIV Services for LGBTQ+ Youth
|
|
Sep 24
|
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
|
|
Sep 23
|
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
|
|
Sep 23
|
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
|
|
Sep 21
|
Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income
|
|
Sep 21
|
3 Dirt Cheap Stocks to Buy Right Now
|
|
Jul 29
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Jul 28
|
Gilead Sciences, Inc.'s (NASDAQ:GILD) one-year returns climbed after last week's 6.1% gain, institutional investors must be happy
|
|
Jul 25
|
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
|
|
Jul 25
|
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
|
|
Jul 25
|
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
|
|
Jul 24
|
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
|
|
Jul 23
|
Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire
|
|
Jul 23
|
ViiV Healthcare’s Dovato as effective as Biktarvy in Phase IV HIV trial
|